https://news.medxy.ai/zh/liver-cancer-boundary-2/Medxy AIzh2026-09-14T10:40:30-07:00绘制肝癌隐匿边界：NCACC揭示驱动肿瘤侵袭的罕见cIgG+上皮细胞 https://news.medxy.ai/ja/liver-cancer-boundary/Medxy AIja2026-09-14T10:40:14-07:00肝臓がんの見えない境界を地図化：NCACCが浸潤を駆動する稀少cIgG陽性上皮細胞を発見 https://news.medxy.ai/vi/liver-cancer-cells/Medxy AIvi2026-09-14T10:39:53-07:00Vẽ lại những vùng khuất của ung thư gan: NCACC phát hiện các tế bào biểu mô cIgG+ hiếm gặp thúc đẩy xâm lấn khối u https://news.medxy.ai/mapping-liver-cancers-hidden-frontiers-ncacc-uncovers-rare-cigg-epithelial-cells-driving-tumor-invasion/Medxy AIen2026-09-14T10:39:37-07:00Mapping Liver Cancer’s Hidden Frontiers: NCACC Uncovers Rare cIgG+ Epithelial Cells Driving Tumor Invasion https://news.medxy.ai/zh/msh3-mlh3-mutations-2/Medxy AIzh2026-09-14T10:39:04-07:00MSH3与MLH3胚系突变可作为抑癌因子，经由ID4高突变特征升高结直肠癌风险 https://news.medxy.ai/ja/msh3-mlh3-cancer-risk/Medxy AIja2026-09-14T10:38:46-07:00MSH3・MLH3 生殖細胞系列変異は大腸癌リスクを高める腫瘍抑制因子か：変異シグネチャー ID4 に注目して https://news.medxy.ai/vi/msh3-mlh3-mutations/Medxy AIvi2026-09-14T10:38:25-07:00Đột biến dòng mầm MSH3 và MLH3: gen ức chế u làm tăng nguy cơ ung thư đại trực tràng với chữ ký tăng đột biến ID4 https://news.medxy.ai/germline-msh3-and-mlh3-mutations-as-tumor-suppressors-elevating-colorectal-cancer-risk-via-hypermutation-signature-id4/Medxy AIen2026-09-14T10:38:05-07:00Germline MSH3 and MLH3 Mutations as Tumor Suppressors Elevating Colorectal Cancer Risk via Hypermutation Signature ID4 https://news.medxy.ai/zh/moyamoya-disease/Medxy AIzh2026-09-14T10:37:25-07:00出血型烟雾病的自然病程与治疗结局：来自中国大型队列的研究启示 https://news.medxy.ai/ja/moyamoya-disease-2/Medxy AIja2026-09-14T10:37:05-07:00出血型モヤモヤ病の自然経過と治療成績：大規模中国コホートから見えた知見 https://news.medxy.ai/vi/73690-2/Medxy AIvi2026-09-14T10:36:44-07:00Diễn tiến tự nhiên và kết quả điều trị bệnh Moyamoya thể xuất huyết https://news.medxy.ai/natural-history-and-treatment-outcomes-in-hemorrhagic-moyamoya-disease-insights-from-a-large-chinese-cohort/Medxy AIen2026-09-14T10:36:24-07:00Natural History and Treatment Outcomes in Hemorrhagic Moyamoya Disease: Insights from a Large Chinese Cohort https://news.medxy.ai/zh/spontaneous-csf-leak/Medxy AIzh2026-09-14T10:35:47-07:00自发性脊髓脑脊液漏所致双臂性肌萎缩：临床特征与手术结局解析 https://news.medxy.ai/ja/spinal-csf-leak-study/Medxy AIja2026-09-14T10:35:24-07:00脊髄性髄液漏に伴う両上肢萎縮性筋力低下の解明：臨床所見と手術成績 https://news.medxy.ai/vi/bilateral-arm-spasticity/Medxy AIvi2026-09-14T10:34:57-07:00Teo cơ hai tay trong rò dịch não tủy cột sống tự phát: Nhận diện lâm sàng và kết quả phẫu thuật https://news.medxy.ai/unraveling-bibrachial-amyotrophy-in-spontaneous-spinal-csf-leaks-clinical-insights-and-surgical-outcomes/Medxy AIen2026-09-14T10:34:32-07:00Unraveling Bibrachial Amyotrophy in Spontaneous Spinal CSF Leaks: Clinical Insights and Surgical Outcomes https://news.medxy.ai/zh/stroke-risk-biomarkers-2/Medxy AIzh2026-09-14T10:33:55-07:00循环代谢物有望成为卒中风险预测新型生物标志物：BiomarCaRE项目研究启示 https://news.medxy.ai/ja/stroke-risk-biomarkers/Medxy AIja2026-09-14T10:33:38-07:00脳卒中リスク予測を支える新規バイオマーカー：循環代謝産物に注目したBiomarCaRE研究 https://news.medxy.ai/vi/circulating-metabolite-biomarker/Medxy AIvi2026-09-14T10:33:14-07:00Chất chuyển hóa tuần hoàn: biomarker mới nổi giúp dự báo nguy cơ đột quỵ từ BiomarCaRE https://news.medxy.ai/circulating-metabolites-as-emerging-biomarkers-for-stroke-risk-prediction-insights-from-the-biomarcare-project/Medxy AIen2026-09-14T10:32:53-07:00Circulating Metabolites as Emerging Biomarkers for Stroke Risk Prediction: Insights from the BiomarCaRE Project https://news.medxy.ai/zh/high-res-tera-analysis/Medxy AIzh2026-09-14T10:30:51-07:00高分辨率断连组分析提升基底动脉闭塞的预后预测，并辅助取栓决策 https://news.medxy.ai/ja/high-res-disconnectome-predicts-outcome/Medxy AIja2026-09-14T10:30:24-07:00高解像度disconnectomeが予後予測精度を高め、脳底動脈閉塞の血栓回収療法判断を支援する https://news.medxy.ai/vi/73670-2/Medxy AIvi2026-09-14T10:30:02-07:00Bản đồ kết nối bị gián đoạn độ phân giải cao giúp nâng cao độ chính xác trong tiên lượng và định hướng quyết định lấy huyết khối ở bệnh nhân tắc động mạch nền https://news.medxy.ai/high-resolution-disconnectome-enhances-prognostic-accuracy-and-guides-thrombectomy-decisions-in-basilar-artery-occlusion/Medxy AIen2026-09-14T10:29:44-07:00High-Resolution Disconnectome Enhances Prognostic Accuracy and Guides Thrombectomy Decisions in Basilar Artery Occlusion https://news.medxy.ai/zh/age-neurodegeneration-bell-palsy/Medxy AIzh2026-09-14T10:29:06-07:00年龄与神经变性协同影响贝尔麻痹恢复：临床意义与启示 https://news.medxy.ai/ja/aging-neurodegeneration-bell-palsy/Medxy AIja2026-09-14T10:28:50-07:00高齢と神経変性の相乗効果がBell麻痺の回復を左右する：臨床的含意 https://news.medxy.ai/vi/age-neurodegeneration-bells-palsy/Medxy AIvi2026-09-14T10:28:31-07:00Ảnh hưởng cộng hưởng của tuổi tác và thoái hóa thần kinh lên hồi phục Bell’s palsy: Ý nghĩa lâm sàng https://news.medxy.ai/synergistic-impact-of-age-and-nerve-degeneration-on-bells-palsy-recovery-clinical-implications/Medxy AIen2026-09-14T10:28:12-07:00Synergistic Impact of Age and Nerve Degeneration on Bell’s Palsy Recovery: Clinical Implications https://news.medxy.ai/zh/genetics-thyroid-nodules/Medxy AIzh2026-09-14T10:27:23-07:00揭开家族性甲状腺滤泡结节性疾病的遗传复杂性 https://news.medxy.ai/ja/genetic-diversity-thyroid/Medxy AIja2026-09-14T10:27:00-07:00家族性甲状腺濾胞性結節性疾患に潜む遺伝的多様性を読み解く https://news.medxy.ai/vi/genetic-complexity-thyroid-disease/Medxy AIvi2026-09-14T10:26:39-07:00Giải mã tính phức tạp di truyền trong bệnh tuyến giáp dạng nhân nang có tính gia đình https://news.medxy.ai/unraveling-genetic-complexity-in-familial-thyroid-follicular-nodular-disease/Medxy AIen2026-09-14T10:26:15-07:00Unraveling Genetic Complexity in Familial Thyroid Follicular Nodular Disease https://news.medxy.ai/zh/perioperative-resuscitation-mortality/Medxy AIzh2026-09-14T10:25:37-07:00围手术期复苏状态限制与术后早期死亡：一项多中心回顾性队列研究的启示 https://news.medxy.ai/ja/perioperative-code-status-impact/Medxy AIja2026-09-14T10:25:17-07:00周術期コードステータス制限は術後早期死亡にどう影響するか：多施設後ろ向きコホート研究からの知見 https://news.medxy.ai/vi/surgery-complications/Medxy AIvi2026-09-14T10:24:56-07:00Hạn chế code status quanh phẫu thuật và tử vong sớm sau mổ: Những phát hiện từ nghiên cứu đoàn hệ hồi cứu đa trung tâm https://news.medxy.ai/perioperative-code-status-limitations-and-early-postoperative-mortality-insights-from-a-multicenter-retrospective-cohort-study/Medxy AIen2026-09-14T10:24:35-07:00Perioperative Code Status Limitations and Early Postoperative Mortality: Insights from a Multicenter Retrospective Cohort Study https://news.medxy.ai/zh/genetic-impact-diabetes/Medxy AIzh2026-09-14T10:23:59-07:00全胰切除联合胰岛自体移植后糖尿病结局的遗传影响 https://news.medxy.ai/ja/73633-2/Medxy AIja2026-09-14T10:23:41-07:00全膵切除術および膵島自家移植後の糖尿病転帰に対する遺伝的影響 https://news.medxy.ai/vi/genetics-diabetes-outcome/Medxy AIvi2026-09-14T10:23:17-07:00Di truyền ảnh hưởng thế nào đến kết cục đái tháo đường sau cắt toàn bộ tụy kèm ghép tự thân đảo tụy? https://news.medxy.ai/genetic-influences-on-diabetes-outcomes-after-total-pancreatectomy-with-islet-autotransplantation/Medxy AIen2026-09-14T10:22:58-07:00Genetic Influences on Diabetes Outcomes After Total Pancreatectomy with Islet Autotransplantation https://news.medxy.ai/zh/anti-inflammatory-diabetes-risk/Medxy AIzh2026-09-14T10:22:21-07:00常见抗炎药或可降低2型糖尿病患者危及视力的糖尿病视网膜病变风险 https://news.medxy.ai/ja/diabetic-retinopathy-risk-2/Medxy AIja2026-09-14T10:22:01-07:002型糖尿病における視機能を脅かす糖尿病網膜症のリスク低下と関連する一般的抗炎症薬 https://news.medxy.ai/vi/anti-inflammatory-drugs-diabetic-retinopathy/Medxy AIvi2026-09-14T10:21:38-07:00Các thuốc kháng viêm thường dùng có liên quan đến giảm nguy cơ bệnh võng mạc đái tháo đường đe dọa thị lực ở đái tháo đường típ 2 https://news.medxy.ai/common-anti-inflammatory-drugs-linked-to-lower-risk-of-vision-threatening-diabetic-retinopathy-in-type-2-diabetes/Medxy AIen2026-09-14T10:21:15-07:00Common Anti-Inflammatory Drugs Linked to Lower Risk of Vision-Threatening Diabetic Retinopathy in Type 2 Diabetes https://news.medxy.ai/zh/episiotomy-types-risk/Medxy AIzh2026-09-14T10:20:31-07:00手术阴道助产中侧切类型对肛门括约肌损伤风险的影响 https://news.medxy.ai/ja/73617-2/Medxy AIja2026-09-14T10:20:13-07:00介助経腟分娩における会陰切開の種類が肛門括約筋損傷のリスクに及ぼす影響 https://news.medxy.ai/vi/episiotomy-type-anal-injury-risk/Medxy AIvi2026-09-14T10:19:55-07:00Loại rạch tầng sinh môn ảnh hưởng thế nào đến nguy cơ chấn thương cơ thắt hậu môn trong sinh ngả âm đạo có can thiệp tại Hoa Kỳ https://news.medxy.ai/impact-of-episiotomy-type-on-anal-sphincter-injury-risk-during-operative-vaginal-delivery-in-the-u-s/Medxy AIen2026-09-14T10:19:36-07:00Impact of Episiotomy Type on Anal Sphincter Injury Risk During Operative Vaginal Delivery in the U.S. https://news.medxy.ai/zh/preventive-mesh-implantation/Medxy AIzh2026-09-14T09:49:47-07:00预防性网片植入可显著降低肝胆胰手术后切口疝风险 https://news.medxy.ai/ja/incisional-hernia-prevention/Medxy AIja2026-09-14T09:49:30-07:00予防的メッシュ留置で肝胆膵手術後の切開ヘルニアリスクを大幅に低減 https://news.medxy.ai/vi/mesh-backup-reduces-hernia-risk/Medxy AIvi2026-09-14T09:49:12-07:00Đặt mesh dự phòng giúp giảm đáng kể nguy cơ thoát vị vết mổ sau phẫu thuật gan-mật-tụy https://news.medxy.ai/prophylactic-mesh-placement-significantly-reduces-incisional-hernia-risk-after-hepatobiliopancreatic-surgery/Medxy AIen2026-09-14T09:48:53-07:00Prophylactic Mesh Placement Significantly Reduces Incisional Hernia Risk After Hepatobiliopancreatic Surgery https://news.medxy.ai/zh/appendiceal-cancer-risk/Medxy AIzh2026-09-14T09:48:19-07:00局限性阑尾腺癌的复发风险评估与辅助化疗作用 https://news.medxy.ai/ja/appendiceal-adenocarcinoma-risk/Medxy AIja2026-09-14T09:48:02-07:00局所性虫垂腺癌における再発リスクと術後補助化学療法の意義を検証する https://news.medxy.ai/vi/recurrence-risk-chemotherapy-appendiceal/Medxy AIvi2026-09-14T09:47:42-07:00Đánh giá nguy cơ tái phát và vai trò của hóa trị bổ trợ trong ung thư biểu mô tuyến ruột thừa khu trú https://news.medxy.ai/evaluating-relapse-risks-and-the-role-of-adjuvant-chemotherapy-in-localized-appendiceal-adenocarcinoma/Medxy AIen2026-09-14T09:47:22-07:00Evaluating Relapse Risks and the Role of Adjuvant Chemotherapy in Localized Appendiceal Adenocarcinoma https://news.medxy.ai/zh/73480-2/Medxy AIzh2026-09-14T09:46:39-07:00推进 SGLT 抑制剂在 1 型糖尿病患者心肾保护中应用的机遇与挑战 https://news.medxy.ai/ja/sglt-in-type-1-diabetes/Medxy AIja2026-09-14T09:46:20-07:001型糖尿病におけるSGLT阻害薬の心腎保護活用を前進させる：機会と課題 https://news.medxy.ai/vi/sglt-inhibitors-heart-kidney/Medxy AIvi2026-09-14T09:45:58-07:00Mở rộng ứng dụng thuốc ức chế SGLT để bảo vệ tim và thận trong đái tháo đường type 1: Cơ hội và thách thức https://news.medxy.ai/advancing-sglt-inhibitor-use-for-heart-and-kidney-protection-in-type-1-diabetes-opportunities-and-challenges/Medxy AIen2026-09-14T09:45:37-07:00Advancing SGLT Inhibitor Use for Heart and Kidney Protection in Type 1 Diabetes: Opportunities and Challenges https://news.medxy.ai/zh/beta-cell-dysfunction-prediction/Medxy AIzh2026-09-14T09:44:41-07:00β细胞功能障碍可提升单一自身抗体阳性个体1型糖尿病进展预测能力 https://news.medxy.ai/ja/beta-cell-dysfunction-prediabetes/Medxy AIja2026-09-14T09:44:24-07:00単一自己抗体陽性者における1型糖尿病進行予測を高めるβ細胞機能障害 https://news.medxy.ai/vi/beta-cell-dysfunction-diabetes/Medxy AIvi2026-09-14T09:44:04-07:00Rối loạn chức năng tế bào β giúp dự báo tốt hơn tiến triển đái tháo đường typ 1 ở người chỉ dương tính với một tự kháng thể https://news.medxy.ai/beta-cell-dysfunction/Medxy AIen2026-09-14T09:43:44-07:00β-Cell Dysfunction Enhances Prediction of Type 1 Diabetes Progression in Individuals with Single Autoantibody Positivity https://news.medxy.ai/zh/hidden-high-risk-phenotype/Medxy AIzh2026-09-14T09:41:58-07:00借助异常检测模型揭示切除后胰腺实性假乳头状肿瘤中的隐匿高风险表型 https://news.medxy.ai/ja/high-risk-phenotype/Medxy AIja2026-09-14T09:41:40-07:00異常検出モデルで明らかにする、切除後solid pseudopapillary tumorに潜む高リスク表現型 https://news.medxy.ai/vi/hidden-high-risk-phenotypes/Medxy AIvi2026-09-14T09:41:23-07:00Phát hiện các kiểu hình nguy cơ cao ẩn giấu trong u nguyên bào giả nhú đặc tụy đã cắt bỏ bằng mô hình phát hiện bất thường https://news.medxy.ai/unveiling-hidden-high-risk-phenotypes-in-resected-solid-pseudopapillary-tumors-using-anomaly-detection-models/Medxy AIen2026-09-14T09:41:03-07:00Unveiling Hidden High-Risk Phenotypes in Resected Solid Pseudopapillary Tumors Using Anomaly-Detection Models https://news.medxy.ai/zh/esophageal-cancer-treatment/Medxy AIzh2026-09-14T09:40:28-07:00老年食管鳞状细胞癌如何权衡疗效与安全性：新辅助免疫放化疗与免疫化疗的比较 https://news.medxy.ai/ja/esophageal-cancer-treatment-2/Medxy AIja2026-09-14T09:40:10-07:00高齢食道扁平上皮癌における有効性と安全性の両立：術前免疫化学放射線療法と免疫化学療法の比較 https://news.medxy.ai/zh/lipid-metabolism-pah/Medxy AIzh2026-09-14T09:40:06-07:00脂质代谢谱揭示后毛细血管性与联合前后毛细血管性肺动脉高压的病理生理差异 https://news.medxy.ai/vi/immunotherapy-esophageal-cancer/Medxy AIvi2026-09-14T09:39:47-07:00Cân bằng giữa hiệu quả và an toàn: Hóa xạ trị miễn dịch tân bổ trợ so với hóa trị miễn dịch ở ung thư biểu mô tế bào vảy thực quản người cao tuổi https://news.medxy.ai/ja/lipid-metabolism-differences/Medxy AIja2026-09-14T09:39:44-07:00脂質代謝プロファイルが明らかにする、後毛細血管性と複合型肺高血圧の病態の違い https://news.medxy.ai/balancing-efficacy-and-safety-neoadjuvant-immunochemoradiotherapy-vs-immunochemotherapy-in-elderly-esophageal-squamous-cell-carcinoma/Medxy AIen2026-09-14T09:39:28-07:00Balancing Efficacy and Safety: Neoadjuvant Immunochemoradiotherapy vs. Immunochemotherapy in Elderly Esophageal Squamous Cell Carcinoma https://news.medxy.ai/vi/73433-2/Medxy AIvi2026-09-14T09:39:21-07:00脂質代謝プロファイルの違いが、毛細血管後性肺高血圧症と前・後毛細血管混合性肺高血圧症の病態生理学的差異を明らかにする https://news.medxy.ai/distinct-lipid-metabolic-profiles-unveil-pathophysiological-differences-between-postcapillary-and-combined-pre-and-postcapillary-pulmonary-hypertension/Medxy AIen2026-09-14T09:38:58-07:00Distinct Lipid Metabolic Profiles Unveil Pathophysiological Differences Between Postcapillary and Combined Pre- and Postcapillary Pulmonary Hypertension https://news.medxy.ai/designing-cardiovascular-outcomes-trials-in-clonal-hematopoiesis-a-precision-medicine-imperative/Medxy AIen2026-09-14T09:37:21-07:00Designing Cardiovascular Outcomes Trials in Clonal Hematopoiesis: A Precision Medicine Imperative https://news.medxy.ai/zh/noninvasive-hf-diagnosis/Medxy AIzh2026-09-14T09:20:03-07:00优化射血分数保留型心力衰竭的无创诊断：结合左心房顺应性评估的增强型运动负荷超声心动图 https://news.medxy.ai/ja/73386-2/Medxy AIja2026-09-14T09:19:38-07:00駆出率保持性心不全の非侵襲的診断の最適化：左房コンプライアンス評価を組み合わせた強化型運動負荷心エコー法 https://news.medxy.ai/vi/73385-2/Medxy AIvi2026-09-14T09:19:15-07:00Tối ưu hóa chẩn đoán không xâm lấn suy tim phân suất tống máu bảo tồn: Siêu âm tim gắng sức cải tiến kết hợp đánh giá độ giãn nở nhĩ trái https://news.medxy.ai/refining-non-invasive-diagnosis-of-hfpef-enhanced-exercise-stress-echocardiography-with-left-atrial-compliance-assessment/Medxy AIen2026-09-14T09:18:54-07:00Refining Non-Invasive Diagnosis of HFpEF: Enhanced Exercise Stress Echocardiography with Left Atrial Compliance Assessment https://news.medxy.ai/zh/portugal-heart-failure/Medxy AIzh2026-09-14T09:18:17-07:00葡萄牙50岁及以上成年人心力衰竭现状：PORTHOS研究揭示患病率与主要表型 https://news.medxy.ai/ja/portugal-heart-failure-2/Medxy AIja2026-09-14T09:17:58-07:00ポルトガル50歳以上成人の心不全：PORTHOS研究が示した有病率と主要表現型の実態 https://news.medxy.ai/vi/heart-failure-porthos-study/Medxy AIvi2026-09-14T09:17:37-07:00Suy tim ở người Bồ Đào Nha từ 50 tuổi trở lên: Những phát hiện từ nghiên cứu PORTHOS về tỷ lệ hiện mắc và các kiểu hình chủ đạo https://news.medxy.ai/heart-failure-in-portuguese-adults-aged-50-and-above-insights-from-the-porthos-study-on-prevalence-and-predominant-phenotypes/Medxy AIen2026-09-14T09:17:18-07:00Heart Failure in Portuguese Adults Aged 50 and Above: Insights from the PORTHOS Study on Prevalence and Predominant Phenotypes https://news.medxy.ai/zh/73377-2/Medxy AIzh2026-09-14T09:16:37-07:00ALB单基因变异：一种与严重高胆固醇血症相关的新型遗传因素 https://news.medxy.ai/ja/73376-2/Medxy AIja2026-09-14T09:16:13-07:00ALB遺伝子バリアント：重度高コレステロール血症に関連する新たな遺伝的要因 https://news.medxy.ai/vi/alb-gene-variant/Medxy AIvi2026-09-14T09:15:48-07:00Biến thể đơn gen ALB: Yếu tố di truyền mới liên quan đến tăng cholesterol máu nặng https://news.medxy.ai/zh/left-atrial-staging/Medxy AIzh2026-09-14T09:14:33-07:00肥厚型心肌病中新发房颤的预测利器：生理性左心房分期 https://news.medxy.ai/ja/73373-2/Medxy AIja2026-09-14T09:14:14-07:00肥大型心筋症における新規発症心房細動の強力な予測ツール：生理学的左房病期分類 https://news.medxy.ai/vi/left-atrial-phases/Medxy AIvi2026-09-14T09:13:52-07:00Phân giai đoạn nhĩ trái sinh lý: Dấu ấn dự báo rung nhĩ mới khởi phát trong bệnh cơ tim phì đại https://news.medxy.ai/physiological-left-atrial-staging-as-a-predictor-of-new-onset-atrial-fibrillation-in-hypertrophic-cardiomyopathy/Medxy AIen2026-09-14T09:13:30-07:00Physiological Left Atrial Staging as a Predictor of New-Onset Atrial Fibrillation in Hypertrophic Cardiomyopathy https://news.medxy.ai/zh/hnrnpk-lactylation-inflammation/Medxy AIzh2026-09-14T09:12:54-07:00代谢与剪接的交汇点：HNRNPK乳酰化驱动心肌缺血/再灌注中的炎症与损伤 https://news.medxy.ai/ja/hnrnpk-lactoylation/Medxy AIja2026-09-14T09:12:32-07:00代謝とスプライシングをつなぐ新機軸：HNRNPKラクトイル化が心筋虚血再灌流の炎症・障害を駆動する https://news.medxy.ai/vi/hnrnpk-inflammation/Medxy AIvi2026-09-14T09:12:09-07:00Nút giao chuyển hóa–nối cắt: Lactyl hóa HNRNPK thúc đẩy viêm và tổn thương trong thiếu máu cục bộ/tái tưới máu cơ tim https://news.medxy.ai/metabolic-splicing-nexus-hnrnpk-lactylation-drives-inflammation-and-injury-in-myocardial-ischemia-reperfusion/Medxy AIen2026-09-14T09:11:48-07:00Metabolic Splicing Nexus: HNRNPK Lactylation Drives Inflammation and Injury in Myocardial Ischemia/Reperfusion https://news.medxy.ai/ja/pembrolizumab-chemotherapy-cervical-cancer/Medxy AIja2026-09-14T09:11:11-07:00子宮頸がんに対するペムブロリズマブ＋化学療法：KEYNOTE-826無作為化臨床試験の5年探索的解析 https://news.medxy.ai/vi/pembrolizumab-cervical-cancer/Medxy AIvi2026-09-14T09:10:51-07:00Pembrolizumab phối hợp hóa trị trong ung thư cổ tử cung: phân tích thăm dò 5 năm từ thử nghiệm lâm sàng ngẫu nhiên KEYNOTE-826 https://news.medxy.ai/pembrolizumab-plus-chemotherapy-for-cervical-cancer-five-year-exploratory-analysis-from-the-keynote-826-randomized-clinical-trial/Medxy AIen2026-09-14T09:10:33-07:00Pembrolizumab Plus Chemotherapy for Cervical Cancer: Five-Year Exploratory Analysis from the KEYNOTE-826 Randomized Clinical Trial https://news.medxy.ai/ja/73360-2/Medxy AIja2026-09-14T09:09:54-07:00軟部組織および内臓平滑筋肉腫の管理に関する国際コンセンサス：平滑筋肉腫グローバル・コンセンサス・グループによる主要な推奨事項（2026年） https://news.medxy.ai/vi/leiomyosarcoma-guidelines/Medxy AIvi2026-09-14T09:09:13-07:00Đồng thuận quốc tế về quản lý sarcoma cơ trơn mô mềm và tạng: Các khuyến nghị chính từ Nhóm Đồng thuận Toàn cầu về Sarcoma cơ trơn (2026) https://news.medxy.ai/zh/soft-tissue-sarcoma-consensus/Medxy AIzh2026-09-14T09:08:34-07:00软组织与内脏平滑肌肉瘤管理国际共识：平滑肌肉瘤全球共识组关键建议（2026） https://news.medxy.ai/international-consensus-on-management-of-soft-tissue-and-visceral-leiomyosarcomas-key-recommendations-from-the-leiomyosarcoma-global-consensus-group-jama-oncology-2026/Medxy AIen2026-09-14T09:08:01-07:00International Consensus on Management of Soft Tissue and Visceral Leiomyosarcomas: Key Recommendations from the Leiomyosarcoma Global Consensus Group (2026) https://news.medxy.ai/zh/andes-hantavirus-study/Medxy AIzh2026-09-13T10:53:29-07:00安第斯病毒相关汉坦病毒心肺综合征重症救治需求与结局的演变：来自智利全国队列的研究 https://news.medxy.ai/ja/andes-virus-icu-trends/Medxy AIja2026-09-13T10:53:11-07:00アンデスウイルス関連ハンタウイルス心肺症候群における集中治療需要と転帰の変化：チリ全国コホートからの知見 https://news.medxy.ai/vi/andes-virus-cardiopulmonary-syndrome/Medxy AIvi2026-09-13T10:52:54-07:00Gánh nặng hồi sức tích cực và kết cục đang thay đổi ở hội chứng tim phổi do Andes virus: dữ liệu từ một đoàn hệ quốc gia Chile https://news.medxy.ai/evolving-critical-care-needs-and-outcomes-in-andes-virus-associated-hantavirus-cardiopulmonary-syndrome-insights-from-a-national-chilean-cohort/Medxy AIen2026-09-13T10:52:37-07:00Evolving Critical Care Needs and Outcomes in Andes Virus-Associated Hantavirus Cardiopulmonary Syndrome: Insights from a National Chilean Cohort https://news.medxy.ai/zh/pediatric-cardiac-failure/Medxy AIzh2026-09-13T10:51:56-07:00儿童急性心肺衰竭分子亚表型的快速免疫测定：临床意义与未来方向 https://news.medxy.ai/ja/pediatric-acute-cardiopulmonary-failure/Medxy AIja2026-09-13T10:51:34-07:00小児急性心肺不全における分子サブフェノタイピング：迅速免疫測定法の臨床的意義と今後の展望 https://news.medxy.ai/vi/rapid-immunoassay/Medxy AIvi2026-09-13T10:51:10-07:00Xét nghiệm miễn dịch nhanh cho phân tầng dưới kiểu hình phân tử trong suy hô hấp–tuần hoàn cấp ở trẻ em: ý nghĩa lâm sàng và định hướng tương lai https://news.medxy.ai/rapid-immunoassay-for-molecular-subphenotyping-in-pediatric-acute-cardiorespiratory-failure-clinical-implications-and-future-directions/Medxy AIen2026-09-13T10:50:48-07:00Rapid Immunoassay for Molecular Subphenotyping in Pediatric Acute Cardiorespiratory Failure: Clinical Implications and Future Directions https://news.medxy.ai/zh/us-child-mental-health-trends/Medxy AIzh2026-09-13T10:49:55-07:00美国儿童心理健康相关急诊就诊与儿科就诊量变化（2016—2022）：综合综述 https://news.medxy.ai/ja/pediatric-mental-health-us/Medxy AIja2026-09-13T10:49:29-07:00米国における小児メンタルヘルス関連救急外来受診と小児受診数の動向（2016～2022年）: 包括的レビュー https://news.medxy.ai/vi/pediatric-ed-mental-health/Medxy AIvi2026-09-13T10:49:03-07:00Gia tăng lượt khám cấp cứu vì sức khỏe tâm thần ở trẻ em tại Hoa Kỳ và vai trò của lưu lượng ED nhi khoa (2016–2022): Tổng quan toàn diện https://news.medxy.ai/childhood-mental-health-related-emergency-department-visits-and-pediatric-volume-dynamics-in-the-us-2016-2022-a-comprehensive-review/Medxy AIen2026-09-13T10:48:37-07:00Childhood Mental Health-Related Emergency Department Visits and Pediatric Volume Dynamics in the US (2016-2022): A Comprehensive Review https://news.medxy.ai/zh/hospital-network-impact/Medxy AIzh2026-09-13T10:47:37-07:0018家医院网络实施揭示：健康社会决定因素筛查的真实影响 https://news.medxy.ai/ja/health-social-screening/Medxy AIja2026-09-13T10:47:22-07:0018病院ネットワーク導入で見えた、健康の社会的決定要因スクリーニングの実際と臨床的意義 https://news.medxy.ai/vi/social-determinants-health-2/Medxy AIvi2026-09-13T10:47:01-07:00Sàng lọc các yếu tố xã hội quyết định sức khỏe: Những phát hiện từ triển khai tại mạng lưới 18 bệnh viện https://news.medxy.ai/unveiling-the-impact-of-social-determinants-of-health-screening-insights-from-an-18-hospital-network-implementation/Medxy AIen2026-09-13T10:46:40-07:00Unveiling the Impact of Social Determinants of Health Screening: Insights from an 18-Hospital Network Implementation https://news.medxy.ai/zh/menopause-hormone-therapy-cvd-risk/Medxy AIzh2026-09-13T10:45:56-07:00绝经激素治疗与中年女性血管舒缩症状相关的心血管风险：来自 SWAN 研究的启示 https://news.medxy.ai/ja/menopause-hormone-therapy-heart-risk/Medxy AIja2026-09-13T10:45:37-07:00閉経期ホルモン療法は中年女性の心血管リスクをどう変えるか：SWAN研究が示す血管運動症状との関連 https://news.medxy.ai/vi/menopause-hormone-therapy-cvd-risk-2/Medxy AIvi2026-09-13T10:45:16-07:00Liệu pháp hormone mãn kinh và nguy cơ tim mạch ở phụ nữ trung niên có triệu chứng vận mạch: Góc nhìn từ nghiên cứu SWAN https://news.medxy.ai/menopausal-hormone-therapy-and-cardiovascular-risk-in-midlife-women-with-vasomotor-symptoms-insights-from-the-swan-study/Medxy AIen2026-09-13T10:44:56-07:00Menopausal Hormone Therapy and Cardiovascular Risk in Midlife Women with Vasomotor Symptoms: Insights from the SWAN Study https://news.medxy.ai/zh/hemoglobin-mortality-risk/Medxy AIzh2026-09-13T10:44:07-07:00血红蛋白水平与死亡风险：来自英国大型队列研究的启示 https://news.medxy.ai/ja/hemoglobin-mortality-risk-3/Medxy AIja2026-09-13T10:43:48-07:00ヘモグロビン値と死亡リスク：英国大規模コホート研究が示す新たな知見 https://news.medxy.ai/vi/hemoglobin-mortality-risk-2/Medxy AIvi2026-09-13T10:43:30-07:00Nồng độ Hemoglobin và Nguy cơ Tử vong: Góc nhìn từ một Nghiên cứu Đoàn hệ Lớn tại Vương quốc Anh https://news.medxy.ai/hemoglobin-levels-and-mortality-risk-insights-from-a-large-uk-cohort-study/Medxy AIen2026-09-13T10:43:11-07:00Hemoglobin Levels and Mortality Risk: Insights from a Large UK Cohort Study https://news.medxy.ai/zh/bcma-car-t-bridge/Medxy AIzh2026-09-13T10:41:50-07:00优化复发/难治性多发性骨髓瘤 BCMA 靶向 CAR T 细胞治疗前的桥接治疗：一项真实世界多中心分析 https://news.medxy.ai/ja/bcma-car-t-therapy/Medxy AIja2026-09-13T10:41:31-07:00再発・難治性多発性骨髄腫におけるBCMA標的CAR-T療法前ブリッジング治療の最適化：リアルワールド多施設解析 https://news.medxy.ai/vi/car-t-therapy-optimization/Medxy AIvi2026-09-13T10:41:07-07:00Tối ưu hóa liệu pháp cầu nối trước điều trị CAR T hướng đích BCMA ở đa u tủy xương tái phát/kháng trị: Phân tích đa trung tâm trong thực hành thực tế https://news.medxy.ai/optimizing-bridging-therapy-before-bcma-directed-car-t-cell-treatment-in-relapsed-refractory-multiple-myeloma-a-real-world-multicenter-analysis/Medxy AIen2026-09-13T10:40:48-07:00Optimizing Bridging Therapy Before BCMA-Directed CAR T-Cell Treatment in Relapsed/Refractory Multiple Myeloma: A Real-World Multicenter Analysis https://news.medxy.ai/zh/myeloproliferative-tumors-trends/Medxy AIzh2026-09-13T10:40:02-07:00骨髓增殖性肿瘤流行病学与生存趋势的演变：来自SEER 2000—2021年的观察 https://news.medxy.ai/ja/myeloproliferative-tumors/Medxy AIja2026-09-13T10:39:40-07:00骨髄増殖性腫瘍の疫学と生存の変遷：SEER 2000–2021からの知見 https://news.medxy.ai/vi/epigenetics-survival-trends/Medxy AIvi2026-09-13T10:39:17-07:00Dịch tễ học biến đổi và xu hướng sống còn trong nhóm tân sinh tăng sinh tủy: dữ liệu từ SEER giai đoạn 2000–2021 https://news.medxy.ai/evolving-epidemiology-and-survival-trends-in-myeloproliferative-neoplasms-insights-from-seer-2000-2021/Medxy AIen2026-09-13T10:38:54-07:00Evolving Epidemiology and Survival Trends in Myeloproliferative Neoplasms: Insights from SEER 2000-2021 https://news.medxy.ai/zh/prmt9-aml-resistance/Medxy AIzh2026-09-13T10:38:07-07:00靶向 PRMT9：破解 AML 中 Venetoclax 耐药的新策略 https://news.medxy.ai/ja/prmt9-targeting-aml/Medxy AIja2026-09-13T10:37:50-07:00AMLのベネトクラクス耐性を打破するPRMT9標的化――治療戦略を塗り替える可能性 https://news.medxy.ai/vi/72944-2/Medxy AIvi2026-09-13T10:37:30-07:00Nhắm đích PRMT9 để khắc phục tình trạng kháng Venetoclax trong bệnh bạch cầu cấp dòng tủy (AML): Một bước ngoặt trong chiến lược điều trị https://news.medxy.ai/targeting-prmt9-to-overcome-venetoclax-resistance-in-aml-a-paradigm-shift-in-therapeutic-strategy/Medxy AIen2026-09-13T10:37:10-07:00Targeting PRMT9 to Overcome Venetoclax Resistance in AML: A Paradigm Shift in Therapeutic Strategy https://news.medxy.ai/zh/72941-2/Medxy AIzh2026-09-13T10:36:30-07:00Astegolimab频繁急性加重的COPD的疗效与安全性研究：来自ALIENTO与ARNASA合并试验 https://news.medxy.ai/ja/copd-astegolimab/Medxy AIja2026-09-13T10:36:06-07:00頻回増悪を伴うCOPDに対するアステゴリマブ：ALIENTOおよびARNASA併合試験からの知見 https://news.medxy.ai/vi/astegolimab-copd-exacerbations/Medxy AIvi2026-09-13T10:35:40-07:00Astegolimab trong bệnh phổi tắc nghẽn mạn tính kịch phát thường xuyên: Góc nhìn từ phân tích gộp ALIENTO và ARNASA https://news.medxy.ai/astegolimab-for-chronic-obstructive-pulmonary-disease-with-frequent-exacerbations-insights-from-the-pooled-aliento-and-arnasa-trials/Medxy AIen2026-09-13T10:35:15-07:00Astegolimab for Chronic Obstructive Pulmonary Disease with Frequent Exacerbations: Insights from the Pooled ALIENTO and ARNASA Trials https://news.medxy.ai/zh/post-cataract-endophthalmitis/Medxy AIzh2026-09-13T10:34:08-07:00白内障术后眼内炎的微生物谱演变与临床特征：一项23年回顾性队列研究 https://news.medxy.ai/ja/72935-2/Medxy AIja2026-09-13T10:33:48-07:00白内障手術後眼内炎における微生物スペクトラムおよび臨床的特徴の変遷：23年間の後ろ向きコホート研究 https://news.medxy.ai/vi/endophthalmitis-post-cataract-surgery/Medxy AIvi2026-09-13T10:33:25-07:00Viêm nội nhãn sau phẫu thuật đục thủy tinh thể: Phổ vi sinh biến đổi và đặc điểm lâm sàng từ một nghiên cứu đoàn hệ hồi cứu kéo dài 23 năm https://news.medxy.ai/evolving-microbial-landscape-and-clinical-profiles-in-postcataract-endophthalmitis-insights-from-a-23-year-retrospective-cohort-study/Medxy AIen2026-09-13T10:33:02-07:00Evolving Microbial Landscape and Clinical Profiles in Postcataract Endophthalmitis: Insights from a 23-Year Retrospective Cohort Study https://news.medxy.ai/zh/hearing-aid-compliance/Medxy AIzh2026-09-13T10:32:14-07:00破解小耳畸形儿童骨导听力设备依从性难题 https://news.medxy.ai/ja/bone-conduction-hearing-aid-adherence/Medxy AIja2026-09-13T10:31:55-07:00小耳症児における骨導補聴器アドヒアランス低下の要因を探る https://news.medxy.ai/vi/bone-conduction-hearing-aids/Medxy AIvi2026-09-13T10:31:30-07:00Những yếu tố cản trở tuân thủ sử dụng thiết bị nghe dẫn truyền xương ở trẻ microtia https://news.medxy.ai/unraveling-adherence-challenges-to-bone-conduction-hearing-devices-in-pediatric-microtia-patients/Medxy AIen2026-09-13T10:31:10-07:00Unraveling Adherence Challenges to Bone Conduction Hearing Devices in Pediatric Microtia Patients https://news.medxy.ai/zh/liver-trauma-treatment/Medxy AIzh2026-09-13T10:30:31-07:00穿透性肝外伤：血管栓塞治疗与手术如何权衡生存获益和住院时长 https://news.medxy.ai/ja/arterial-embolization-surgery/Medxy AIja2026-09-13T10:30:12-07:00穿通性肝外傷における動脈塞栓術と手術：生存率と入院期間の最適なバランス https://news.medxy.ai/vi/angioembolization-vs-surgery/Medxy AIvi2026-09-13T10:29:50-07:00Angioembolization so với phẫu thuật trong chấn thương gan xuyên thấu: Cân bằng giữa sống còn và thời gian nằm viện https://news.medxy.ai/angioembolization-vs-surgery-in-penetrating-hepatic-trauma-balancing-survival-and-hospital-stay/Medxy AIen2026-09-13T10:29:31-07:00Angioembolization vs. Surgery in Penetrating Hepatic Trauma: Balancing Survival and Hospital Stay https://news.medxy.ai/zh/bridge-gap-transgender-care/Medxy AIzh2026-09-13T10:19:00-07:00缩小差距：提升意大利内分泌科医师在跨性别医疗中的能力 https://news.medxy.ai/ja/transgender-care-italy/Medxy AIja2026-09-13T10:18:44-07:00イタリアの内分泌専門医に求められるトランスジェンダー医療の知識と対応力の強化 https://news.medxy.ai/vi/transgender-healthcare-italy/Medxy AIvi2026-09-13T10:18:27-07:00Thu hẹp khoảng cách: Nâng cao năng lực chăm sóc sức khỏe người chuyển giới của các bác sĩ nội tiết Ý https://news.medxy.ai/bridging-the-gap-enhancing-italian-endocrinologists-competence-in-transgender-health-care/Medxy AIen2026-09-13T10:18:10-07:00Bridging the Gap: Enhancing Italian Endocrinologists’ Competence in Transgender Health Care https://news.medxy.ai/zh/thyroid-eye-disease-2/Medxy AIzh2026-09-13T10:17:37-07:00重新认识甲状腺眼病：为什么临床指标至关重要——聚焦 Innovate TED Initiative https://news.medxy.ai/ja/thyroid-eye-disease/Medxy AIja2026-09-13T10:17:21-07:00甲状腺眼症で臨床指標が重要な理由：Innovate TED Initiative の取り組みを読み解 https://news.medxy.ai/vi/thyroid-eye-index/Medxy AIvi2026-09-13T10:16:58-07:00Vì sao chỉ số đo lường lại quan trọng trong bệnh mắt tuyến giáp: Khám phá sáng kiến Innovate TED https://news.medxy.ai/why-metrics-matter-in-thyroid-eye-disease-exploring-the-innovate-ted-initiative/Medxy AIen2026-09-13T10:16:39-07:00Why Metrics Matter in Thyroid Eye Disease: Exploring the Innovate TED Initiative https://news.medxy.ai/widening-the-spectrum-of-disease-expression-due-to-heterozygous-variants-in-efemp1/Medxy AIen2026-09-13T10:16:06-07:00Widening the Spectrum of Disease Expression due to Heterozygous Variants in EFEMP1 https://news.medxy.ai/zh/bell-electrophysiology/Medxy AIzh2026-09-13T10:15:29-07:00Bell 麻痹预后评估再提升：超越 House-Brackmann 分级的电生理检查 https://news.medxy.ai/ja/bell-palsy-prognosis/Medxy AIja2026-09-13T10:15:04-07:00Bell麻痺の予後を高める：House-Brackmann分類を超える電気生理学的評価 https://news.medxy.ai/vi/electrophysiology-prediction/Medxy AIvi2026-09-13T10:14:45-07:00Liệt Bell: xét nghiệm điện sinh lý thần kinh giúp dự đoán tiên lượng chính xác hơn ngoài thang House-Brackmann https://news.medxy.ai/enhancing-prognosis-in-bell-palsy-electrodiagnostic-testing-beyond-house-brackmann-grade/Medxy AIen2026-09-13T10:14:25-07:00Enhancing Prognosis in Bell Palsy: Electrodiagnostic Testing Beyond House-Brackmann Grade https://news.medxy.ai/zh/pesticide-exposure-anosmia-2/Medxy AIzh2026-09-13T10:13:48-07:00高农药暴露事件与嗅觉功能障碍：来自农业队列的主客观证据整合 https://news.medxy.ai/ja/pesticide-exposure-olfactory-impairment/Medxy AIja2026-09-13T10:13:26-07:00高農薬曝露イベントと嗅覚機能障害：農業コホートからみた主観的・客観的エビデンスの統合 https://news.medxy.ai/vi/pesticide-exposure-anosmia/Medxy AIvi2026-09-13T10:12:58-07:00Phơi nhiễm thuốc trừ sâu mức cao và rối loạn khứu giác: Tích hợp bằng chứng chủ quan và khách quan từ các quần thể nông nghiệp https://news.medxy.ai/high-pesticide-exposure-events-and-olfactory-dysfunction-integrating-subjective-and-objective-evidence-from-agricultural-cohorts/Medxy AIen2026-09-13T10:12:37-07:00High Pesticide Exposure Events and Olfactory Dysfunction: Integrating Subjective and Objective Evidence from Agricultural Cohorts https://news.medxy.ai/ja/type1-diabetes-consensus/Medxy AIja2026-09-13T10:03:33-07:00一般集団への膵島自己抗体スクリーニング、早期1型糖尿病発見に向けた新国際コンセンサス https://news.medxy.ai/vi/international-consensus/Medxy AIvi2026-09-13T10:02:58-07:00Đồng thuận quốc tế mới: sàng lọc dân số chung bằng tự kháng thể đảo tụy để phát hiện đái tháo đường týp 1 giai đoạn sớm https://news.medxy.ai/zh/early-type1-diabetes/Medxy AIzh2026-09-13T10:02:25-07:00国际新共识：通过普通人群胰岛自身抗体筛查识别早期1型糖尿病 https://news.medxy.ai/new-international-consensus-screening-the-general-population-for-islet-autoantibodies-to-detect-early-stage-type-1-diabetes/Medxy AIen2026-09-13T10:01:59-07:00New International Consensus: Screening the General Population for Islet Autoantibodies to Detect Early-Stage Type 1 Diabetes https://news.medxy.ai/zh/teplizumab-type-1-diabetes-2/Medxy AIzh2026-09-13T10:00:44-07:00teplizumab可保留新诊断青少年1型糖尿病的β细胞功能：PROTECT试验按方案分析的新启示 https://news.medxy.ai/ja/teplizumab-type-1-diabetes/Medxy AIja2026-09-13T10:00:26-07:00テプリズマブは新規発症の小児1型糖尿病でβ細胞機能を守る：PROTECT試験PP解析から得られた知見 https://news.medxy.ai/vi/teplizumab-beta-cell-function/Medxy AIvi2026-09-13T10:00:08-07:00Teplizumab giúp bảo tồn chức năng tế bào beta ở người trẻ mới mắc đái tháo đường type 1: phân tích theo phác đồ từ thử nghiệm PROTECT https://news.medxy.ai/teplizumab-preserves-beta-cell-function-in-youth-with-newly-diagnosed-type-1-diabetes-insights-from-the-protect-trial-per-protocol-analysis/Medxy AIen2026-09-13T09:59:48-07:00Teplizumab Preserves Beta Cell Function in Youth with Newly Diagnosed Type 1 Diabetes: Insights from the PROTECT Trial Per-Protocol Analysis https://news.medxy.ai/zh/thyroxine-binding-protein/Medxy AIzh2026-09-13T09:59:11-07:00转甲状腺素蛋白心脏淀粉样变性的分子亚型：来自蛋白质组学分析与塔法米地疗效的启示 https://news.medxy.ai/ja/transthyretin-amyloidosis-2/Medxy AIja2026-09-13T09:58:54-07:00トランスサイレチン心アミロイドーシスの分子サブタイプ：プロテオミクス解析とタファミジス有効性から見えた新知見 https://news.medxy.ai/vi/transthyretin-amyloidosis-3/Medxy AIvi2026-09-13T09:58:33-07:00Các phân nhóm phân tử trong bệnh amyloidosis tim do transthyretin: Góc nhìn từ proteomics và hiệu quả của tafamidis https://news.medxy.ai/molecular-subtypes-in-transthyretin-cardiac-amyloidosis-insights-from-proteomics-profiling-and-tafamidis-efficacy/Medxy AIen2026-09-13T09:58:12-07:00Molecular Subtypes in Transthyretin Cardiac Amyloidosis: Insights from Proteomics Profiling and Tafamidis Efficacy https://news.medxy.ai/zh/adult-unilateral-deafness-implant/Medxy AIzh2026-09-13T09:57:34-07:00长期单侧耳聋成年人是否仍适合人工耳蜗植入？多中心研究带来新证据 https://news.medxy.ai/ja/cochlear-implant-study/Medxy AIja2026-09-13T09:57:16-07:00長期片側難聴の成人における人工内耳埋め込み術を再考する：多施設研究からのエビデンス https://news.medxy.ai/vi/cochlear-implant-adults-unilateral-deafness/Medxy AIvi2026-09-13T09:56:55-07:00Cấy ốc tai điện tử ở người lớn bị điếc một bên kéo dài: Bằng chứng từ nghiên cứu đa trung tâm https://news.medxy.ai/reevaluating-cochlear-implantation-in-adults-with-long-term-unilateral-deafness-evidence-from-a-multicenter-study/Medxy AIen2026-09-13T09:56:37-07:00Reevaluating Cochlear Implantation in Adults with Long-Term Unilateral Deafness: Evidence from a Multicenter Study https://news.medxy.ai/zh/wilms-tumor-survival-2/Medxy AIzh2026-09-13T09:56:01-07:00Wilms瘤淋巴结评估与生存结局：一项大型 COG 肾肿瘤研究的启示 https://news.medxy.ai/ja/wilms-tumor-lymph-node/Medxy AIja2026-09-13T09:55:44-07:00好組織型Wilms腫瘍におけるリンパ節評価と生存転帰：大規模COG腎腫瘍研究からの知見 https://news.medxy.ai/vi/wilms-tumor-survival/Medxy AIvi2026-09-13T09:55:24-07:00Đánh giá hạch bạch huyết và kết cục sống còn trong u Wilms mô học thuận lợi: Phát hiện từ một nghiên cứu lớn của COG về u thận https://news.medxy.ai/lymph-node-assessment-and-survival-outcomes-in-favorable-histology-wilms-tumor-insights-from-a-large-cog-renal-tumor-study/Medxy AIen2026-09-13T09:55:06-07:00Lymph Node Assessment and Survival Outcomes in Favorable Histology Wilms Tumor: Insights from a Large COG Renal Tumor Study https://news.medxy.ai/zh/pouchitis-antibiotic-challenges/Medxy AIzh2026-09-13T09:54:29-07:00pouchitis：抗生素短期有效，但菌株更替与毒力回归带来长期挑战 https://news.medxy.ai/ja/pouchitis-antibiotic-effects/Medxy AIja2026-09-13T09:54:13-07:00pouchitisにおける短期的な抗菌薬効果と長期的課題：微生物株動態と病原性再出現の示唆 https://news.medxy.ai/vi/antibiotic-challenges/Medxy AIvi2026-09-13T09:53:53-07:00Viêm túi chứa: kháng sinh giúp lui bệnh ngắn hạn nhưng còn nhiều thách thức lâu dài do tái nổi lên của chủng vi khuẩn và độc lực https://news.medxy.ai/short-term-antibiotic-success-but-long-term-challenges-in-pouchitis-insights-into-microbial-strain-dynamics-and-virulence-re-emergence/Medxy AIen2026-09-13T09:53:37-07:00Short-Term Antibiotic Success but Long-Term Challenges in Pouchitis: Insights into Microbial Strain Dynamics and Virulence Re-Emergence https://news.medxy.ai/zh/ptau217-apoe-cognitive-decline-2/Medxy AIzh2026-09-13T09:53:01-07:00血浆 p-tau217 联合 APOE 基因型：跨多族裔人群认知衰退风险预测的新策略 https://news.medxy.ai/ja/plasma-p-tau217-apoe-prediction/Medxy AIja2026-09-13T09:52:42-07:00多様な集団の認知機能低下予測に向けた血漿p-tau217とAPOE遺伝子型の統合 https://news.medxy.ai/vi/ptau217-apoe-cognitive-decline/Medxy AIvi2026-09-13T09:52:21-07:00Kết hợp p-tau217 huyết tương và kiểu gen APOE để dự đoán suy giảm nhận thức ở các quần thể đa dạng https://news.medxy.ai/integrating-plasma-p-tau217-and-apoe-genotype-to-predict-cognitive-decline-across-diverse-populations/Medxy AIen2026-09-13T09:52:01-07:00Integrating Plasma p-tau217 and APOE Genotype to Predict Cognitive Decline Across Diverse Populations https://news.medxy.ai/zh/immune-checkpoint-vegf-effects-2/Medxy AIzh2026-09-13T09:51:24-07:00免疫检查点与VEGF抑制剂的血管效应再认识：基于PET显像与免疫分型的研究 https://news.medxy.ai/ja/immune-checkpoint-vegf-effects/Medxy AIja2026-09-13T09:51:04-07:00免疫チェックポイント阻害薬とVEGF阻害薬が血管に及ぼす影響を読み解く：PET画像と免疫プロファイリングからの示唆 https://news.medxy.ai/vi/immune-checkpoint-vegf-impact/Medxy AIvi2026-09-13T09:50:43-07:00Giải mã tác động mạch máu của các thuốc ức chế điểm kiểm soát miễn dịch và VEGF: Góc nhìn từ PET và phân tích miễn dịch https://news.medxy.ai/unraveling-the-vascular-impact-of-immune-checkpoint-and-vegf-inhibitors-insights-from-pet-imaging-and-immune-profiling/Medxy AIen2026-09-13T09:50:23-07:00Unraveling the Vascular Impact of Immune Checkpoint and VEGF Inhibitors: Insights from PET Imaging and Immune Profiling